# Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

> **NCT04321070** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 550 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Clindamycin Phosphate
- **DRUG:** Clindamycin Phosphate RLD
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04321070
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2019-12-14
- **Final completion:** 2020-03-06
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04321070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04321070, "Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04321070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*